Literature DB >> 27212111

The microbiota and immune response during Clostridium difficile infection.

Erica L Buonomo1, William A Petri2.   

Abstract

Clostridium difficile is a gram-positive, spore forming anaerobe that infects the gut when the normal microbiota has been disrupted. C. difficile infection (CDI) is the most common cause of hospital acquired infection in the United States, and the leading cause of death due to gastroenteritis. Patients suffering from CDI have varying symptoms which range from mild diarrhea to pseudomembranous colitis and death. The involvement of the immune response to influence disease severity is just beginning to be investigated. There is evidence that the immune response can facilitate either protective or pathogenic phenotypes, suggesting it plays a multifaceted role during CDI. In addition to the immune response, the microbiota is pivotal in dictating the pathogenesis to CDI. A healthy microbiota effectively inhibits infection by restricting the ability of C. difficile to expand in the colon. Thus, understanding which immune mediators and components of the microbiota play beneficial roles during CDI will be important to future therapeutic developments. This review outlines how the microbiota can modulate specific immune mediators, such as IL-23 and others, to influence disease outcome.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clostridium difficile; Colitis; Fecal transplant; Immune response; Inflammation; Innate; Microbiota

Mesh:

Year:  2016        PMID: 27212111      PMCID: PMC5050085          DOI: 10.1016/j.anaerobe.2016.05.009

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  70 in total

Review 1.  Recurrent clostridium difficile.

Authors:  Seema Maroo; J Thomas Lamont
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

2.  The normal microbial flora as a major stimulus for proliferation of plasma cells synthesizing IgA in the gut. The germ-free intestinal tract.

Authors:  P A Crabbé; H Bazin; H Eyssen; J F Heremans
Journal:  Int Arch Allergy Appl Immunol       Date:  1968

3.  Nucleotide-binding oligomerization domain 1 mediates recognition of Clostridium difficile and induces neutrophil recruitment and protection against the pathogen.

Authors:  Mizuho Hasegawa; Takashi Yamazaki; Nobuhiko Kamada; Kazuki Tawaratsumida; Yun-Gi Kim; Gabriel Núñez; Naohiro Inohara
Journal:  J Immunol       Date:  2011-03-16       Impact factor: 5.422

4.  Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile Infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals.

Authors:  Becky A Miller; Luke F Chen; Daniel J Sexton; Deverick J Anderson
Journal:  Infect Control Hosp Epidemiol       Date:  2011-04       Impact factor: 3.254

5.  Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection.

Authors:  M Warny; J P Vaerman; V Avesani; M Delmée
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

6.  Evidence for a cross-talk between human neutrophils and Th17 cells.

Authors:  Martin Pelletier; Laura Maggi; Alessandra Micheletti; Elena Lazzeri; Nicola Tamassia; Claudio Costantini; Lorenzo Cosmi; Claudio Lunardi; Francesco Annunziato; Sergio Romagnani; Marco A Cassatella
Journal:  Blood       Date:  2009-11-04       Impact factor: 22.113

Review 7.  New trends in Clostridium difficile virulence and pathogenesis.

Authors:  C Denève; C Janoir; I Poilane; C Fantinato; A Collignon
Journal:  Int J Antimicrob Agents       Date:  2009-03       Impact factor: 5.283

8.  Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile.

Authors:  Charlie G Buffie; Vanni Bucci; Richard R Stein; Peter T McKenney; Lilan Ling; Asia Gobourne; Daniel No; Hui Liu; Melissa Kinnebrew; Agnes Viale; Eric Littmann; Marcel R M van den Brink; Robert R Jenq; Ying Taur; Chris Sander; Justin R Cross; Nora C Toussaint; Joao B Xavier; Eric G Pamer
Journal:  Nature       Date:  2014-10-22       Impact factor: 49.962

9.  Nfil3 is crucial for development of innate lymphoid cells and host protection against intestinal pathogens.

Authors:  Theresa L Geiger; Michael C Abt; Georg Gasteiger; Matthew A Firth; Margaret H O'Connor; Clair D Geary; Timothy E O'Sullivan; Marcel R van den Brink; Eric G Pamer; Alan M Hanash; Joseph C Sun
Journal:  J Exp Med       Date:  2014-08-11       Impact factor: 14.307

10.  Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation.

Authors:  Nicholas Arpaia; Clarissa Campbell; Xiying Fan; Stanislav Dikiy; Joris van der Veeken; Paul deRoos; Hui Liu; Justin R Cross; Klaus Pfeffer; Paul J Coffer; Alexander Y Rudensky
Journal:  Nature       Date:  2013-11-13       Impact factor: 49.962

View more
  11 in total

1.  Loss of Interleukin-10 (IL-10) Signaling Promotes IL-22-Dependent Host Defenses against Acute Clostridioides difficile Infection.

Authors:  Emily S Cribas; Joshua E Denny; Jeffrey R Maslanka; Michael C Abt
Journal:  Infect Immun       Date:  2021-04-16       Impact factor: 3.441

Review 2.  The Inflammasome and Type-2 Immunity in Clostridium difficile Infection.

Authors:  Alexandra Donlan; William A Petri
Journal:  Clin Colon Rectal Surg       Date:  2020-02-25

Review 3.  Type 3 Immunity during Clostridioides difficile Infection: Too Much of a Good Thing?

Authors:  Mahmoud M Saleh; William A Petri
Journal:  Infect Immun       Date:  2019-12-17       Impact factor: 3.441

4.  Faecalibacterium prausnitzii and a Prebiotic Protect Intestinal Health in a Mouse Model of Antibiotic and Clostridium difficile Exposure.

Authors:  Sanjoy Roychowdhury; Jennifer Cadnum; Bryan Glueck; Mark Obrenovich; Curtis Donskey; Gail A M Cresci
Journal:  JPEN J Parenter Enteral Nutr       Date:  2018-01-31       Impact factor: 4.016

5.  Development and Validation of a Prediction Model for Mortality and Adverse Outcomes Among Patients With Peripheral Eosinopenia on Admission for Clostridium difficile Infection.

Authors:  Audrey S Kulaylat; Erica L Buonomo; Kenneth W Scully; Christopher S Hollenbeak; Heather Cook; William A Petri; David B Stewart
Journal:  JAMA Surg       Date:  2018-12-01       Impact factor: 14.766

6.  Evaluating the effect of Clostridium difficile conditioned medium on fecal microbiota community structure.

Authors:  Sabina Horvat; Aleksander Mahnic; Martin Breskvar; Saso Dzeroski; Maja Rupnik
Journal:  Sci Rep       Date:  2017-11-27       Impact factor: 4.379

7.  Nonsteroidal Anti-inflammatory Drugs Alter the Microbiota and Exacerbate Clostridium difficile Colitis while Dysregulating the Inflammatory Response.

Authors:  Damian Maseda; Joseph P Zackular; Bruno Trindade; Leslie Kirk; Jennifer Lising Roxas; Lisa M Rogers; Mary K Washington; Liping Du; Tatsuki Koyama; V K Viswanathan; Gayatri Vedantam; Patrick D Schloss; Leslie J Crofford; Eric P Skaar; David M Aronoff
Journal:  mBio       Date:  2019-01-08       Impact factor: 7.867

Review 8.  Clostridium difficile - From Colonization to Infection.

Authors:  Holger Schäffler; Anne Breitrück
Journal:  Front Microbiol       Date:  2018-04-10       Impact factor: 5.640

Review 9.  Challenges for Clinical Development of Vaccines for Prevention of Hospital-Acquired Bacterial Infections.

Authors:  Isabelle Bekeredjian-Ding
Journal:  Front Immunol       Date:  2020-08-05       Impact factor: 7.561

Review 10.  Bacterial Gut Microbiota and Infections During Early Childhood.

Authors:  Sergio George; Ximena Aguilera; Pablo Gallardo; Mauricio Farfán; Yalda Lucero; Juan Pablo Torres; Roberto Vidal; Miguel O'Ryan
Journal:  Front Microbiol       Date:  2022-01-05       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.